VINCENT TAM to Drug Combinations
This is a "connection" page, showing publications VINCENT TAM has written about Drug Combinations.
Connection Strength
1.630
-
In vitro evaluation of using ceftazidime/avibactam against carbapenem-resistant Acinetobacter baumannii. J Glob Antimicrob Resist. 2024 Sep; 38:252-255.
Score: 0.866
-
In vitro model to simulate multiple drugs with distinct elimination half-lives. Int J Antimicrob Agents. 2023 Oct; 62(4):106924.
Score: 0.202
-
Optimal ceftazidime/avibactam dosing exposure against KPC-producing Klebsiella pneumoniae. J Antimicrob Chemother. 2022 10 28; 77(11):3130-3137.
Score: 0.192
-
Real life experience with ceftolozane/tazobactam therapy for Pseudomonas aeruginosa bacteremia. J Chemother. 2021 Dec; 33(8):595-597.
Score: 0.172
-
Novel modeling framework to guide design of optimal dosing strategies for ?-lactamase inhibitors. Antimicrob Agents Chemother. 2012 May; 56(5):2237-40.
Score: 0.092
-
A novel method to evaluate ceftazidime/avibactam therapy in patients with carbapenemase-producing Enterobactericeae (CPE)?bloodstream infections. Int J Antimicrob Agents. 2023 Apr; 61(4):106760.
Score: 0.049
-
New ?-Lactam-?-Lactamase Inhibitor Combinations. Clin Microbiol Rev. 2020 12 16; 34(1).
Score: 0.042
-
Pharmacodynamic activity of amphotericin B deoxycholate is associated with peak plasma concentrations in a neutropenic murine model of invasive pulmonary aspergillosis. Antimicrob Agents Chemother. 2006 Feb; 50(2):469-73.
Score: 0.015